~~<i id='F22E462A1A'><strike id='F22E462A1A'><tt id='F22E462A1A'><pre id='F22E462A1A'></pre></tt></strike></i>~~

Home» focus» explore

explore

author：fashion 2025-10-06 16:43:30 Page View：691

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alabama frozen embryo ruling has major implications for IVF clinics
Next article： Alkermes shareholders re

focus

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

MollyFerguson/STATThisweek,anencouragingturnaroundforOcularTherapeutix,achatwithAlnylam’sCEOdefendin

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Study: Black kids more likely to die after surgery than white kids

AdobeEvenamongapparentlyhealthychildren,Blackpatientsarealmostthreeandahalftimesmorelikelytodiewithi